TP53 and non-small cell lung carcinoma: In addition to the synergy of AZD6738 with cisplatin observed in ATM-deficient H23 cells, shRNA knockdown of ATM resulted in similar synergy with cisplatin in vitro in two p53-wildtype NSCLC cell lines.